Trillium Therapeutics Inc (TRIL.CA) Stock Income Statement
Canada - Toronto Stock Exchange - TSX:TRIL -
23.33
+0.11 (+0.47%)
| TTM (2021-9-30) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 40.00K | 150.00K | 120.00K | 0.00 | 0.00 | |||
| Operating Expenses | 57.52M | 61.60M | 32.41M | 37.43M | 31.58M | |||
| Research and Development | 35.55M | 25.35M | 26.69M | 29.49M | 25.98M | |||
| Selling, General, and Administrative Expenses | 21.96M | 36.26M | 5.72M | 3.85M | 2.97M | |||
| Operating Income | -57.47M | -61.46M | -32.29M | -37.43M | -31.58M | |||
| Interest Income/Expense | 1.81M | 2.21M | -5.77M | 4.57M | -3.16M | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | 0.00 | N/A | |||
| Income Before Taxes | -55.66M | -59.24M | -38.05M | -32.86M | -34.74M | |||
| Income Tax | 237.00K | 100.00K | 30.00K | 10.00K | 0.00 | |||
| Net Income | -55.90M | -59.35M | -38.08M | -32.87M | -34.75M | |||
| EBITDA | -57.17M | -60.87M | -31.68M | -34.99M | -27.96M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.54 | -0.70 | -1.51 | -2.36 | -3.56 | |||
| Non GAAP EPS | N/A | -0.79 | -1.68 | -2.36 | -3.59 | |||
| Statistics | ||||||||
| Profit Margin | -139737.50% | -39566.67% | -31733.33% | N/A | N/A | |||
| Operating Profit Margin | -143667.50% | -40973.33% | -26908.33% | N/A | N/A | |||
All data in USD